Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells

ATC is a very rare, but extremely aggressive form of thyroid malignancy, responsible for the highest mortality rate registered for thyroid cancer. In patients without known genetic aberrations, the current treatment is still represented by palliative surgery and systemic mono- or combined chemotherapy, which is often not fully effective for the appearance of drug resistance. Comprehension of the mechanisms involved in the development of the resistance is therefore an urgent issue to suggest novel therapeutic approaches for this very aggressive malignancy. In this study, we created a model of anaplastic thyroid cancer (ATC) cells resistant to paclitaxel and investigated the characteristics of these cells by analyzing the profile of gene expression and comparing it with that of paclitaxel-sensitive original ATC cell lines. In addition, we evaluated the effects of Dihydrotanshinone I (DHT) on the viability and invasiveness of paclitaxel-resistant cells. ATC paclitaxel-resistant cells highlighted an overexpression of ABCB1 and a hyper-activation of the NF-κB compared to sensitive cells. DHT treatment resulted in a reduction of viability and clonogenic ability of resistant cells. Moreover, DHT induces a decrement of NF-κB activity in SW1736-PTX and 8505C-PTX cells. In conclusion, to the best of our knowledge, the results of the present study are the first to demonstrate the antitumor effects of DHT on ATC cells resistant to Paclitaxel in vitro.

Download Full-text

Antitumor Effect of Various Phytochemicals on Diverse Types of Thyroid Cancers

Nutrients ◽

10.3390/nu11010125 ◽

2019 ◽

Vol 11 (1) ◽

pp. 125 ◽

Cited By ~ 9

Author(s):

Hye-Ji Shin ◽

Kyung-A Hwang ◽

Kyung-Chul Choi

Keyword(s):

Thyroid Cancer ◽

Animal Studies ◽

Anaplastic Thyroid Cancer ◽

Thyroid Cancers ◽

Anticancer Efficacy ◽

Other Substances ◽

English Articles ◽

Thyroid Cancer Cells ◽

Inhibit Cell Proliferation

Thyroid cancers developed from the tissues of the thyroid gland are classified into papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic thyroid cancer (ATC). Although thyroid cancers have been generally known as mild forms of cancer, undifferentiated MTC and ATC have a more unfavorable prognosis than differentiated PTC and FTC because they are more aggressive and early metastatic. A variety of therapies such as surgery, radiotherapy, and chemotherapy have been currently used to treat thyroid cancer, but they still have limitations including drug resistance or unfavorable side effects. Phytochemicals are plant-derived chemicals having various physiological activities that are expected to be effective in cancer treatment. In this review, anticancer efficacy of phytochemicals, such as resveratrol, genistein, curcumin, and other substances in each type of thyroid cancer was introduced with their chemopreventive mechanisms. English articles related with thyroid cancer and anti-thyroid cancer of phytochemicals were searched from PubMed and Google Scholar. This article mainly focused on in vitro or animal studies on phytochemicals with anti-thyroid cancer activity. These various phytochemicals have been shown to induce apoptosis in all types of thyroid cancer cells, inhibit cell proliferation and invasion, and to be helpful in enhancing the effect of radioiodine therapy that is a typical therapy to thyroid cancer. These results suggest that thyroid cancer can be more effectively treated by the combinations of phytochemicals and the existing therapies or substances.

Download Full-text

A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro

Surgery ◽

10.1016/j.surg.2020.06.009 ◽

2021 ◽

Vol 169 (1) ◽

pp. 34-42

Author(s):

Chitra Subramanian ◽

Rebecca Gorney ◽

Ton Wang ◽

Derek Ge ◽

Nina Zhang ◽

...

Keyword(s):

Thyroid Cancer ◽

Heat Shock ◽

Heat Shock Protein ◽

Cancer Cells ◽

Drug Resistant ◽

Protein Inhibitor ◽

Follicular Thyroid Cancer ◽

Thyroid Cancer Cells ◽

Resistant Cells

Download Full-text

High Energy Shock Waves Activate 5′-Aminolevulinic Acid and Increase Permeability to Paclitaxel: Antitumor Effects of a New Combined Treatment on Anaplastic Thyroid Cancer Cells

Thyroid ◽

10.1089/thy.2006.0142 ◽

2007 ◽

Vol 17 (2) ◽

pp. 91-99 ◽

Cited By ~ 13

Author(s):

M. G. Catalano ◽

L. Costantino ◽

N. Fortunati ◽

O. Bosco ◽

M. Pugliese ◽

...

Keyword(s):

Thyroid Cancer ◽

Shock Waves ◽

Cancer Cells ◽

Aminolevulinic Acid ◽

Combined Treatment ◽

Anaplastic Thyroid Cancer ◽

High Energy ◽

Antitumor Effects ◽

Thyroid Cancer Cells

Download Full-text

Antitumor effects of anlotinib in thyroid cancer

Endocrine Related Cancer ◽

10.1530/erc-17-0558 ◽

2019 ◽

Vol 26 (1) ◽

pp. 153-164 ◽

Cited By ~ 11

Author(s):

Xianhui Ruan ◽

Xianle Shi ◽

Qiman Dong ◽

Yang Yu ◽

Xiukun Hou ◽

...

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Kinase Inhibitor ◽

Anaplastic Thyroid Cancer ◽

Cancer Type ◽

Papillary Thyroid ◽

Antitumor Effects ◽

Effective Therapeutic Strategy

There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.

Download Full-text

Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-006-0185-x ◽

2006 ◽

Vol 58 (4) ◽

pp. 460-470 ◽

Cited By ~ 29

Author(s):

Junichi Kurebayashi ◽

Sumiko Okubo ◽

Yutaka Yamamoto ◽

Masahiko Ikeda ◽

Katsuhiro Tanaka ◽

...

Keyword(s):

Thyroid Cancer ◽

Cancer Cells ◽

Anaplastic Thyroid Cancer ◽

Antitumor Effects ◽

Thyroid Cancer Cells

Download Full-text

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo

Nanotheranostics ◽

10.7150/ntno.53844 ◽

2021 ◽

Vol 5 (2) ◽

pp. 143-154

Author(s):

Le Xiong ◽

Xiao-Min Lin ◽

Jun-Hua Nie ◽

Hai-Shan Ye ◽

Jia Liu

Keyword(s):

Thyroid Cancer ◽

Cancer Cells ◽

Anaplastic Thyroid Cancer ◽

Thyroid Cancer Cells

Download Full-text

Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo

Endocrine Related Cancer ◽

10.1677/erc-07-0243 ◽

2008 ◽

Vol 15 (2) ◽

pp. 499-510 ◽

Cited By ~ 39

Author(s):

M Celano ◽

S Schenone ◽

D Cosco ◽

M Navarra ◽

E Puxeddu ◽

...

Keyword(s):

Thyroid Cancer ◽

Cancer Cells ◽

Anaplastic Thyroid Cancer ◽

Cytotoxic Effects ◽

Thyroid Cancer Cells

Download Full-text

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models

Cancers ◽

10.3390/cancers13040862 ◽

2021 ◽

Vol 13 (4) ◽

pp. 862

Author(s):

Keisuke Enomoto ◽

Shun Hirayama ◽

Naoko Kumashiro ◽

Xuefeng Jing ◽

Takahito Kimura ◽

...

Keyword(s):

Thyroid Cancer ◽

Protein Kinase ◽

Kinase Inhibitor ◽

Treatment Success ◽

Anaplastic Thyroid Cancer ◽

Mek Inhibitor ◽

Mitogen Activated Protein Kinase ◽

Antitumor Effects ◽

Mek Inhibitors

E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer. However, a majority of patients do not continue lenvatinib intake due to disease progression or significant toxicity. To improve treatment success rates, we propose the combination of lenvatinib with mitogen-activated protein kinase (MEK) inhibitors. To test this hypothesis, we tested the effects of lenvatinib with the MEK inhibitor U0126 in vitro using two human anaplastic thyroid cancer (ATC) cell lines, 8505C and TCO1, and with another MEK inhibitor, selumetinib (AZD6244), in an ATC mouse model. We found that the combination of lenvatinib with MEK inhibitors enhanced the antitumor effects of monotherapy with either agent in vitro and in vivo, and these effects may be through the AKT (Protein Kinase B) and extracellular signal-regulated kinase (ERK) signaling pathways. Furthermore, the combination does not have significant adverse effects in the ATC mouse models in terms of body weight, blood biochemical parameters, and histopathology. In conclusion, the combination of lenvatinib with an MEK inhibitor is a potentially viable therapeutic approach for ATC treatment.

Download Full-text